Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Russia

- PMLiVE

Novavax begins phase 2 portion of COVID-19 vaccine trial

Trial will enrol up to 1,500 participants in the US and Australia

- PMLiVE

COVID-19 vaccine ‘unlikely’ to be available this year, says UK’s chief medical officer

Chris Whitty warns that there is no certainty that an effective vaccine will be available before winter 2021

- PMLiVE

FDA grants emergency approval for blood plasma treatments for COVID-19

Emergency approval granted despite concerns from top US health officials

- PMLiVE

Pifzer, BioNTech eye October approval for mRNA-based COVID-19 vaccine

Companies share additional phase 1 safety and tolerability data

- PMLiVE

US payments for COVID-19 vaccines tied to specific timing milestones

Full pay-out is dependent on achieving regulatory approval by certain dates

- PMLiVE

Roche, Regeneron partner on COVID-19 antibody cocktail

Collaboration agreement will bolster global development and manufacturing capabilities

- PMLiVE

Britain ramps up COVID-19 testing to track spread of infections

Regular testing will increase from 28,000 people per fortnight to 150,000 by October

- PMLiVE

Vaccine nationalism must be prevented, says WHO director-general

Tedros Adhanom Ghebreyesus warns against supply nationalism

- PMLiVE

Matt Hancock unveils new National Institute for Health Protection

Public Health England to be replaced with new government body

AstraZeneca AZ

AZ inks deal with EU for 400 million doses of COVID-19 vaccine

Doses will be available to all EU member states at no profit during pandemic

- PMLiVE

Public Health England to be axed over coronavirus response

Report from The Sunday Telegraph details plans to replace agency

- PMLiVE

COVID-19 vaccine approval unlikely before November, says US NIH director

US National Institutes of Health Director Francis Collins cautioned against unrealistic timelines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links